Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees as of November 30, 2022. The stock options have an exercise price of $5.29 per share, equivalent to Karyopharm's closing stock price on the grant date. Both stock options and RSUs will vest over four years, with specific conditions for early exercise tied to employment termination scenarios. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at facilitating recruitment.
Karyopharm Therapeutics (NASDAQ: KPTI), a leader in novel cancer therapies, announced its participation in two upcoming investor conferences in November 2022. The Jefferies 2022 London Healthcare Conference is scheduled for November 15, 2022, at 3:35 a.m. ET, featuring a fireside chat. The Piper Sandler 34th Annual Healthcare Conference will take place on November 29, 2022, at 11:30 a.m. ET, with a podium presentation. Webcasts of both events will be accessible for 90 days post-event on the company's investor webpage.
Karyopharm Therapeutics (KPTI) reported Q3 2022 total revenue of $36.1 million, with net product revenue from XPOVIO at $32.0 million, a 20% increase from Q3 2021. The company initiated a Phase 3 study for selinexor as maintenance therapy in advanced endometrial cancer. Encouraging data from a Phase 1 study of selinexor combined with ruxolitinib in myelofibrosis was highlighted, showing positive efficacy results. Karyopharm maintains its 2022 revenue guidance of $155 million to $165 million, emphasizing a cash runway into early 2024.
Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis. Preliminary efficacy showed 79% of patients achieved a ≥35% reduction in spleen volume at 12 weeks, with 86% at 24 weeks. The treatment also demonstrated significant symptom reduction in 69% of evaluable patients. Common adverse events were manageable, with no dose-limiting toxicities reported. Data on selinexor's effectiveness in triple-class refractory multiple myeloma will also be presented at the upcoming ASH Annual Meeting.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 23,200 shares and 16,000 restricted stock units (RSUs) to seven new employees as of October 31, 2022. These awards were made under the 2022 Inducement Stock Incentive Plan as an incentive for new hires in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $4.76 per share and will vest over four years, while RSUs will also vest over the same period. Both awards include conditions related to employment status and change in control provisions.
Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced that the European Commission has granted orphan medicinal product designation for selinexor to treat myelofibrosis (MF). This follows the FDA's orphan designation for selinexor in May 2022. Karyopharm is studying selinexor as a monotherapy and in combination with ruxolitinib for MF. Selinexor is a first-in-class XP01 inhibitor. The designation provides financial and regulatory incentives, including 10-year marketing exclusivity in the EU after approval.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2022 financial results on November 3, 2022. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead product, XPOVIO® (selinexor), which is approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets. Investors interested in KPTI should tune in to the call for key financial insights.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on October 3, 2022, the granting of stock options and restricted stock units (RSUs) to new employees, including Executive VP Lisa DiPaolo. On September 30, 2022, a stock option to purchase 1,200 shares at $5.46 per share was awarded to a new hire, while DiPaolo received options for 100,000 shares and 65,000 RSUs at the same exercise price. The awards vest over four years, linked to ongoing employment. These inducements comply with Nasdaq rules and aim to attract talent essential for the company's innovative cancer therapies.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced participation in two investor conferences this September. The Morgan Stanley 20th Annual Global Healthcare Conference will take place on September 12, 2022, at 12:30 p.m. ET, followed by the Baird 2022 Global Healthcare Conference on September 13, 2022, at 12:50 p.m. ET. Live webcasts and slides will be available on their website for 90 days post-event. Karyopharm specializes in oral cancer treatments, including its lead compound, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on Sept. 1, 2022, the approval of stock options for 40,800 shares and 28,000 restricted stock units (RSUs) to eight new employees, aimed at incentivizing key talent. The stock options are priced at $5.06, aligning with the common stock's closing price as of August 31, 2022. Each equity award will vest over four years, contingent on continued employment. Additionally, 7,500 RSUs were granted to Johanna Shulman, VP, Program Lead, with specific vesting terms defined. These grants comply with Nasdaq Listing Rule 5635(c)(4).